IFNG and neoplasm: After treatment with quadrigemine I, the inhibition rates for IFN-γ were 9.95 ± 1.01% and 49.42 ± 0.71% in serum, 6.35 ± 2.05% and 43.13 ± 0.60% in liver tissue, 21.21 ± 0.21% and 46.59 ± 0.66% in spleen tissue, and 3.97 ± 0.88% and 38.03 ± 0.22% in tumor tissue.